NCT03914612 2026-05-04Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting813 enrolled 16 charts 1 FDA